Unlock instant, AI-driven research and patent intelligence for your innovation.

Furo[3,2-d]pyrimidine HIV-1 inhibitor as well as preparation method and application thereof

A HIV-1, 2-d technology, applied in pharmaceutical formulations, antiviral agents, medical preparations containing active ingredients, etc., can solve problems such as toxic and side effects, pharmacokinetic properties, etc., and achieve high application value.

Inactive Publication Date: 2018-09-28
SHANDONG UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, problems such as drug resistance, side effects and poor pharmacokinetic properties of NNRTIs in clinical treatment limit their clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Furo[3,2-d]pyrimidine HIV-1 inhibitor as well as preparation method and application thereof
  • Furo[3,2-d]pyrimidine HIV-1 inhibitor as well as preparation method and application thereof
  • Furo[3,2-d]pyrimidine HIV-1 inhibitor as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1: Preparation of 4-((2-chlorofuro[3,2-d]pyrimidin-4-yl)oxy)-3,5-dimethylbenzonitrile (5)

[0034]

[0035] Weigh 4-hydroxy-3,5-dimethylbenzonitrile (1.5g, 10mmol) and potassium carbonate (1.7g, 12mmol) in 30mL of DMF, stir at room temperature for 15 minutes, then add 2,4-dichlorofuran And[3,2-d]pyrimidine 1 (1.9g, 10mmol) continued to stir at room temperature for 2h (TLC detected that the reaction was complete). After a large amount of white solid was formed, 100 mL of ice water was slowly added thereto, filtered, dried in vacuo, and recrystallized from ethanol to obtain Intermediate 5. White solid, yield 96%, melting point 225-228°C. 1 H NMR (400MHz, DMSO-d 6 )δ8.66 (d, J=2.2Hz, 1H, C 6 -furopyrimidine-H),7.78(s,2H,C 3 ,C 5 -Ph-H), 7.32(d,J=2.2Hz,1H,C 7 -furopyrimidine-H),2.14(s,6H).HRMS: m / z 300.1111[M+1] + .C 15 h 10 ClN 3 o 2 (299.0462).

Embodiment 2

[0036]Example 2: 3,5-Dimethyl-4-((2-(piperidin-4-ylamino)furo[3,2-d]pyrimidin-4-yl)oxy)benzonitrile (7) preparation of

[0037]

[0038] 5 (0.95g, 3.17mmol), N-Boc-4-aminopiperidine (0.83g, 3.80mmol) and potassium carbonate (0.87g, 6.33mmol) were added to 5mL of DMF in turn, then heated to reflux for 10h (TLC detection). After the reaction was cooled to room temperature, the reaction solution was slowly added dropwise to 50 mL of water, and a large amount of yellow solid was formed. After standing for 30min, filter and vacuum dry to obtain the crude product. Weigh the crude product (1.26g, 2.53mmol) and dissolve it in 4mL of dichloromethane, add 2.22mL of trifluoroacetic acid (30mmol), and stir at room temperature for 3-5h (TLC detection). Then the pH of the reaction solution was adjusted to 9 with saturated sodium bicarbonate solution, extracted with dichloromethane (3×5 mL), washed with saturated sodium chloride solution, and the organic layer was dried over anhydrous ...

Embodiment 3

[0039] Embodiment 3: the preparation of target compound A1-A6

[0040] Weigh compound 7 (0.5mmol) in 5mL DMF, then add potassium carbonate (0.14g, 1.0mmol) and substituted benzyl chloride or benzyl bromide (0.6mmol) in sequence, and stir at room temperature for 6-8h (TLC detection). Add 20 mL of saturated sodium chloride solution to the reaction solution, wash with ethyl acetate (3×10 mL), separate the organic layer, and dry over anhydrous sodium sulfate. Then, the crude product of the target compound was separated by flash column chromatography, and then recrystallized in the ethyl acetate-petroleum ether system to obtain the target compound A1-A6.

[0041] 4-((4-((4-(4-cyano-2,6-dimethylphenoxy)furo[3,2-d]pyrimidin-2-yl)amino)piperidin-1-yl )Methyl)benzenesulfonamide (A1)

[0042]

[0043] White solid, yield 66%, melting point 206-208°C. 1 H NMR (400MHz, DMSO-d 6 )δ8.23(d,J=2.1Hz, 1H,C 6 -furopyrimidine-H), 7.78 (d, J=8.0Hz, 2H, C 3 ,C 5 -Ph'-H),7.72(s,2H,C 3 ,C ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a furo[3,2-d]pyrimidine HIV-1 inhibitor as well as a preparation method and application thereof. The compound has a structure as shown in a formula I. The invention further relates to a pharmaceutical composition containing the compound having the structure as shown in the formula I and an application of the compound and a composition containing one or more of the compoundto preparation of drugs for treating and preventing human immunodeficiency virus (HIV).

Description

technical field [0001] The invention belongs to the technical field of organic compound synthesis and medical application, and specifically relates to a furo[3,2-d]pyrimidine HIV-1 inhibitor and its preparation method and application. Background technique [0002] AIDS is a clinical syndrome that is infected by human immunodeficiency virus (HIV) and causes deficiencies in human defense functions, and is prone to opportunistic infections and tumors. It is an infectious disease that seriously threatens human life and health in the world today, and belongs to "major new drug creation" It is one of the 10 major diseases listed in major science and technology projects that seriously endanger the health of our people. So far, no anti-HIV drug with independent intellectual property rights has been successfully marketed in China. Therefore, based on independent innovation, research and development of original drugs for the treatment of AIDS with independent intellectual property ri...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D491/048A61K31/519A61P31/18
CPCA61P31/18C07D491/048Y02P20/55
Inventor 刘新泳康东伟展鹏方增军汪昭
Owner SHANDONG UNIV